A method of predicting a lethal outcome EARLY destructive pancreatitis severe diseases early

摘要

method u043fu0440u043eu0433u043du043eu0437u0438u0440u043eu0432u0430u043du0438u00a0 u043bu0435u0447u0435u043du0438u00a0 early lethality of patients with destructive u043fu0430u043du043au0440u0435u0430u0442u0438u0442u043eu043c u0442u00a0u0436u0435u043bu043eu0439 degree by u0438u0437u0443u0447u0435u043du0438u00a0 clinical data, laboratory studies of blood, u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 so that after the primary clinical and laboratory u043eu0431u0441u043bu0435u0434u043eu0432u0430u043du0438u00a0 sick u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 u0432u0435u0440u043eu00a0u0442u043du043eu0441u0442u044c u0440u0430u0437u0432u0438u0442u0438u00a0 patient early fly u044cu043du043eu0433u043e outcome on the formula;where y is the u0432u0435u0440u043eu00a0u0442u043du043eu0441u0442u044c u0440u0430u0437u0432u0438u0442u0438u00a0 early death;;x1 is the age of the patient, to 56 years old, 1 point, 2 points more than 56 years;;h2 - biochemical index: b = cap + m + ast + cd;where bi is the biochemical index, cap - glucose mmol / l, the level of urea in mmol / l - aspartate transaminase, ast in mmol / l, the cd is the level of creatinine in mmol / l respectively, b 15.9 - 1 score, b 15.9 - 2 points;;the x3 - score u0442u00a0u0436u0435u0441u0442u0438 acute pancreatitis on u0432.u0431.u043au0440u0430u0441u043du043eu0440u043eu0433u043eu0432u0443, score u0442u00a0u0436u0435u0441u0442u0438 7.5 - 1 score, score u0442u00a0u0436u0435u0441u0442u0438 7.5 - 2 points;;u04454 - traditional operative treatment, u043fu0440u0438u043cu0435u043du00a0u043bu043eu0441u044c - 1 point, u043fu0440u0438u043cu0435u043du00a0u043bu043eu0441u044c - 0 points;;x5 - u043cu0438u043du0438u0438u043du0432u0430u0437u0438u0432u043du043eu0435 operative treatment, u043fu0440u0438u043cu0435u043du00a0u043bu043eu0441u044c - 1 point, u043fu0440u0438u043cu0435u043du00a0u043bu043eu0441u044c - 0 points;;u04456 - application of the u0441u0430u043du0434u043eu0441u0442u0430u0442u0438u043du0430 (u043eu043au0442u0440u0435u043eu0442u0438u0434u0430), u043fu0440u0438u043cu0435u043du00a0u043bu0441u00a0 - 1 point, u043fu0440u0438u043cu0435u043du00a0u043bu0441u00a0 - 0 points;;u04457 - the use of inhibitors u043fu0440u043eu0442u0435u0430u0437, u043fu0440u0438u043cu0435u043du00a0u043bu0438u0441u044c - 1 point, u043fu0440u0438u043cu0435u043du00a0u043bu0438u0441u044c - 0 points;;x8 - application of the therapeutic u043fu043bu0430u0437u043cu0430u0444u0435u0440u0435u0437u0430 (number of sessions);and the importance of Y0,5 u043eu0436u0438u0434u0430u0435u0442u0441u00a0 u0432u044bu0441u043eu043au0430u00a0 u0432u0435u0440u043eu00a0u0442u043du043eu0441u0442u044c early lethal outcome.